$GH
Guardant Health, Inc. Stock $gh

$gh Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000162828019003139 Filed on March 19, 2019

Income Statement

Concept	2019 Q1	2017 Q4	2016
Revenue	$36.66M		$25.25M
YoY Change	119.6%
Cost Of Revenue	$13.54M		$22.10M
YoY Change	46.38%
Gross Profit	$23.12M		$3.100M
YoY Change	210.75%
Gross Profit Margin	63.07%		12.28%
Selling, General & Admin	$30.47M		$36.11M
YoY Change	70.87%
% of Gross Profit	131.78%		1164.94%
Research & Development	$16.32M		$10.86M
YoY Change	97.65%
% of Gross Profit	70.57%		350.29%
Depreciation & Amortization	$2.354M	$1.400M	$3.693M
YoY Change	68.75%
% of Gross Profit	10.18%		119.13%
Operating Expenses	$46.78M		$46.97M
YoY Change	79.35%
Operating Profit	-$23.66M		-$43.85M
YoY Change	26.91%
Interest Expense	$293.0K		$3.018M
YoY Change	-11.48%
% of Operating Profit
Other Income/Expense, Net	$147.0K		-$1.000K
YoY Change	-96.46%
Pretax Income	-$21.33M		-$46.13M
YoY Change	54.04%
Income Tax	$26.00K		$6.000K
% Of Pretax Income
Net Earnings	-$21.35M		-$46.14M
YoY Change	54.23%
Net Earnings / Revenue	-58.25%		-182.74%
Basic Earnings Per Share
Diluted Earnings Per Share	-$303.1K		-$551.4K
COMMON SHARES
Basic Shares Outstanding	85.93M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2017 Q4	2016
SHORT-TERM ASSETS
Cash & Short-Term Investments	$466.9M		$95.30M
YoY Change
Cash & Equivalents	$153.8M	$72.28M	$33.60M
Short-Term Investments	$313.1M		$61.70M
Other Short-Term Assets	$6.200M		$1.600M
YoY Change
Inventory	$10.26M	$7.287M	$2.800M
Prepaid Expenses
Receivables	$40.60M	$12.79M	$3.500M
Other Receivables	$0.00		$0.00
Total Short-Term Assets	$512.3M	$242.9M	$103.1M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$30.58M	$16.04M	$12.60M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$25.90M		$0.00
YoY Change
Other Assets	$2.862M	$1.974M	$800.0K
YoY Change
Total Long-Term Assets	$66.92M	$100.0M	$13.50M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$512.3M	$242.9M	$103.1M
Total Long-Term Assets	$66.92M	$100.0M	$13.50M
Total Assets	$579.2M	$342.9M	$116.6M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.163M	$4.998M	$3.200M
YoY Change
Accrued Expenses	$9.137M	$6.406M	$4.000M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00		$0.00
YoY Change
Long-Term Debt Due	$100.0K		$100.0K
YoY Change
Total Short-Term Liabilities	$48.19M	$19.63M	$14.30M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K		$16.90M
YoY Change
Other Long-Term Liabilities	$150.0K	$0.00	$5.700M
YoY Change
Total Long-Term Liabilities	$150.0K	$0.00	$22.60M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$48.19M	$19.63M	$14.30M
Total Long-Term Liabilities	$150.0K	$0.00	$22.60M
Total Liabilities	$64.54M	$34.33M	$36.90M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$275.9M	-$195.7M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$468.1M	$308.6M	$79.70M
YoY Change
Total Liabilities & Shareholders Equity	$579.2M	$342.9M	$116.6M
YoY Change

Cashflow Statement

Concept	2019 Q1	2017 Q4	2016
OPERATING ACTIVITIES
Net Income	-$21.35M		-$46.14M
YoY Change	54.23%
Depreciation, Depletion And Amortization	$2.354M	$1.400M	$3.693M
YoY Change	68.75%
Cash From Operating Activities	-$4.303M	-$17.99M	-$36.71M
YoY Change	-34.4%
INVESTING ACTIVITIES
Capital Expenditures	$2.705M	-$2.960M	$1.766M
YoY Change	-32.73%
Acquisitions
YoY Change
Other Investing Activities	$18.03M	-$92.87M	$27.97M
YoY Change	44.36%
Cash From Investing Activities	$15.33M	-$95.83M	$26.20M
YoY Change	80.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$100.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.288M	50.00K	$39.84M
YoY Change	80.58%
NET CHANGE
Cash From Operating Activities	-$4.303M	-17.99M	-$36.71M
Cash From Investing Activities	$15.33M	-95.83M	$26.20M
Cash From Financing Activities	$2.288M	50.00K	$39.84M
Net Change In Cash	$13.25M	-113.8M	$29.33M
YoY Change	316.77%
FREE CASH FLOW
Cash From Operating Activities	-$4.303M	-$17.99M	-$36.71M
Capital Expenditures	$2.705M	-$2.960M	$1.766M
Free Cash Flow	-$7.008M	-$15.03M	-$38.48M
YoY Change	-33.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q4
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001576280
CY2018Q2	dei	Entity Public Float EntityPublicFloat	0	USD
CY2017Q4	gh	Convertible Preferred Stock Value Outstanding ConvertiblePreferredStockValueOutstanding	499974000	USD
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	85928193	shares
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018Q4	gh	Convertible Preferred Stock Value Outstanding ConvertiblePreferredStockValueOutstanding	0	USD
CY2016	gh	Costof Development Services CostofDevelopmentServices	59000	USD
CY2018	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2017	gh	Costof Development Services CostofDevelopmentServices	2735000	USD
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2016	gh	Conversionof Stock Upon Initial Public Offering ConversionofStockUponInitialPublicOffering	0	USD
CY2017	gh	Conversionof Stock Upon Initial Public Offering ConversionofStockUponInitialPublicOffering	0	USD
CY2018	gh	Conversionof Stock Upon Initial Public Offering ConversionofStockUponInitialPublicOffering	499974000	USD
CY2017Q2	gh	Convertible Preferred Stock Conversion Price ConvertiblePreferredStockConversionPrice	10.1338
CY2017Q2	gh	Convertible Preferred Stock Conversion Price ConvertiblePreferredStockConversionPrice	9.8329
CY2018	dei	Entity Registrant Name EntityRegistrantName	Guardant Health, Inc.
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	dei	Trading Symbol TradingSymbol	GH
CY2017Q4	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	0	USD
CY2018Q4	gh	Accrued Expenses Propertyand Equipment Current AccruedExpensesPropertyandEquipmentCurrent	343000	USD
CY2017Q4	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	7708000	USD
CY2018Q4	gh	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	7338000	USD
CY2018	gh	Capital Leases Contractual Term CapitalLeasesContractualTerm	P4Y
CY2016	gh	Capitalized License Fees Financed Through Future Royalty Payment CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment	0	USD
CY2017	gh	Capitalized License Fees Financed Through Future Royalty Payment CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment	6302000	USD
CY2018	gh	Capitalized License Fees Financed Through Future Royalty Payment CapitalizedLicenseFeesFinancedThroughFutureRoyaltyPayment	0	USD
CY2017Q4	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	255779000	USD
CY2018Q4	gh	Cash Cash Equivalentsand Debt Securities Fair Value CashCashEquivalentsandDebtSecuritiesFairValue	381776000	USD
CY2017Q4	gh	Classof Warrantor Right Timeto Expiry ClassofWarrantorRightTimetoExpiry	P10Y
CY2018Q4	gh	Contractual Obligation Future Minimum Payments Interest Includedin Payments ContractualObligationFutureMinimumPaymentsInterestIncludedinPayments	6111000	USD
CY2018Q4	gh	Contractual Obligation Future Minimum Payments Present Valueof Net Minimum Payments ContractualObligationFutureMinimumPaymentsPresentValueofNetMinimumPayments	7338000	USD
CY2018	gh	Costof Development Services CostofDevelopmentServices	3364000	USD
CY2016	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	22065000	USD
CY2017	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	28883000	USD
CY2018	gh	Costsof Precision Oncology Testing CostsofPrecisionOncologyTesting	39846000	USD
CY2017Q4	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	256310000	USD
CY2018Q4	gh	Debt Securities Availableforsaleand Cashand Cash Equivalents Amortized Cost DebtSecuritiesAvailableforsaleandCashandCashEquivalentsAmortizedCost	381858000	USD
CY2017Q4	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	561000	USD
CY2018Q4	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	814000	USD
CY2017Q4	gh	Estimated Litigation Liability Settlement Current EstimatedLitigationLiabilitySettlementCurrent	3000000	USD
CY2018Q4	gh	Estimated Litigation Liability Settlement Current EstimatedLitigationLiabilitySettlementCurrent	0	USD
CY2016	gh	Income Lossfrom Continuing Operationsbefore Equity Method Investments Federal Income Taxes Noncontrolling Interest IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest	-46133000	USD
CY2017	gh	Income Lossfrom Continuing Operationsbefore Equity Method Investments Federal Income Taxes Noncontrolling Interest IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest	-83214000	USD
CY2018	gh	Income Lossfrom Continuing Operationsbefore Equity Method Investments Federal Income Taxes Noncontrolling Interest IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsFederalIncomeTaxesNoncontrollingInterest	-84313000	USD
CY2016	gh	Income Lossfrom Continuing Operationsbefore Equity Method Investments Foreign Income Taxes Noncontrolling Interest IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest	0	USD
CY2017	gh	Income Lossfrom Continuing Operationsbefore Equity Method Investments Foreign Income Taxes Noncontrolling Interest IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest	0	USD
CY2018	gh	Income Lossfrom Continuing Operationsbefore Equity Method Investments Foreign Income Taxes Noncontrolling Interest IncomeLossfromContinuingOperationsbeforeEquityMethodInvestmentsForeignIncomeTaxesNoncontrollingInterest	88000	USD
CY2016	gh	Increasein Capital Expenditures Incurredbut Notyet Paid IncreaseinCapitalExpendituresIncurredbutNotyetPaid	34000	USD
CY2017	gh	Increasein Capital Expenditures Incurredbut Notyet Paid IncreaseinCapitalExpendituresIncurredbutNotyetPaid	591000	USD
CY2018	gh	Increasein Capital Expenditures Incurredbut Notyet Paid IncreaseinCapitalExpendituresIncurredbutNotyetPaid	897000	USD
CY2018Q4	gh	Stock Issued During Period Shares Exerciseof Warrants StockIssuedDuringPeriodSharesExerciseofWarrants	6548	shares
CY2018	gh	Stock Issued During Period Value Conversionof Convertible Preferred Stockto Common Stock Upon Initial Public Offering StockIssuedDuringPeriodValueConversionofConvertiblePreferredStocktoCommonStockUponInitialPublicOffering	0	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1470000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6406000	USD
CY2016	gh	Noncash Interest Expense NoncashInterestExpense	1024000	USD
CY2017	gh	Noncash Interest Expense NoncashInterestExpense	685000	USD
CY2018	gh	Noncash Interest Expense NoncashInterestExpense	-13000	USD
CY2018	gh	Numberof Parties With Patent License Agreement NumberofPartiesWithPatentLicenseAgreement	4	party
CY2016	gh	Offering Costs Incurredbut Notyet Paid OfferingCostsIncurredbutNotyetPaid	0	USD
CY2017	gh	Offering Costs Incurredbut Notyet Paid OfferingCostsIncurredbutNotyetPaid	0	USD
CY2018	gh	Offering Costs Incurredbut Notyet Paid OfferingCostsIncurredbutNotyetPaid	89000	USD
CY2016	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	379000	USD
CY2017	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	25844000	USD
CY2018	gh	Payment Relatedto Settlementof Debtand Buyoutof Royalty Obligations PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations	0	USD
CY2016	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	753000	USD
CY2017	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	7754000	USD
CY2018	gh	Revenuefrom Development Services RevenuefromDevelopmentServices	12232000	USD
CY2016	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	24496000	USD
CY2017	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	42088000	USD
CY2018	gh	Revenuefrom Precision Oncology Testing RevenuefromPrecisionOncologyTesting	78407000	USD
CY2016	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.03
CY2017	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.02
CY2018	gh	Royalty Expense Percentageof Precision Oncology Testing Revenue RoyaltyExpensePercentageofPrecisionOncologyTestingRevenue	0.02
CY2016	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Cancellationsin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross	543764	shares
CY2018	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Cancellationsin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantCancellationsinPeriodGross	795371	shares
CY2018	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Forfeituresin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantForfeituresinPeriodGross	508847	shares
CY2016	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Grantsin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross	4685577	shares
CY2018	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Options Availablefor Grant Grantsin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsAvailableforGrantGrantsinPeriodGross	2088639	shares
CY2018	gh	Sharebased Compensation Arrangementby Sharebased Payment Award Shares Available For Grant Repurchaseof Early Exercised Shares SharebasedCompensationArrangementbySharebasedPaymentAwardSharesAvailableForGrantRepurchaseofEarlyExercisedShares	1230	shares
CY2016	gh	Stock Issued During Period Value Exerciseof Warrants StockIssuedDuringPeriodValueExerciseofWarrants	0	USD
CY2017	gh	Stock Issued During Period Value Exerciseof Warrants StockIssuedDuringPeriodValueExerciseofWarrants	12000	USD
CY2018	gh	Stock Issued During Period Value Exerciseof Warrants StockIssuedDuringPeriodValueExerciseofWarrants	45000	USD
CY2016	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	0	USD
CY2018	gh	Stock Issued During Period Value Stock Options Exercised Early StockIssuedDuringPeriodValueStockOptionsExercisedEarly	0	USD
CY2016	gh	Unrealized Translations Losseson Obligation Relatedto Royalty UnrealizedTranslationsLossesonObligationRelatedtoRoyalty	0	USD
CY2017	gh	Unrealized Translations Losseson Obligation Relatedto Royalty UnrealizedTranslationsLossesonObligationRelatedtoRoyalty	980000	USD
CY2018	gh	Unrealized Translations Losseson Obligation Relatedto Royalty UnrealizedTranslationsLossesonObligationRelatedtoRoyalty	-357000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4998000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10642000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12787000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35690000	USD
CY2016	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-287000	USD
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-359000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	412000	USD
CY2017Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	905000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7081000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-3670000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-1971000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	336000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1791000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	766000	USD
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	707000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10696000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16634000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-532000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-83000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4900000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	764033000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	283000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	103000	USD
CY2016	us-gaap	Advertising Expense AdvertisingExpense	597000	USD
CY2017	us-gaap	Advertising Expense AdvertisingExpense	290000	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	223000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-6851000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2017	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	66000	USD
CY2018Q4	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	228000	USD
CY2018	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	164000	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32565000	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50415000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	51707000	shares
CY2017Q4	us-gaap	Assets Assets	342938000	USD
CY2018Q4	us-gaap	Assets Assets	587403000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	242935000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	468991000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	235000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	531000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	317000	USD
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	199000	USD
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	97000	USD
CY2016	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	468000	USD
CY2017	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	346000	USD
CY2018	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2017Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	460000	USD
CY2018Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	119000	USD
CY2017Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	1100000	USD
CY2018Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	504000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	285000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	141000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	36000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	108000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	69000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	216000	USD
CY2017Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	349000	USD
CY2018Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	294000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72280000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	140544000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4259000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33591000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72596000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	140544000	USD
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	29332000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	39005000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	67948000	USD
CY2012Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.14
CY2012Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	495775	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	313741	shares
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	67675796	shares
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11144912	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0000001
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	38000	USD
CY2018Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	1431000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	1431000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0000001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	111853396	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11896882	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	85832454	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11896882	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85832454	shares
CY2017Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	USD
CY2018Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46215000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-83667000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84614000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-46215000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-83667000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-83814000	USD
CY2018Q4	us-gaap	Contractual Obligation ContractualObligation	13449000	USD
CY2018Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	5722000	USD
CY2018Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	1717000	USD
CY2018Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	1717000	USD
CY2018Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	1431000	USD
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	69096000	USD
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	126454000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	183581000	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	6000	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	7000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	34000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7000	USD
CY2017Q2	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	20700000	USD
CY2017Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	4911000	USD
CY2018Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	12986000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6537000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7844000	USD
CY2017Q4	us-gaap	Deferred Revenue DeferredRevenue	3100000	USD
CY2018Q4	us-gaap	Deferred Revenue DeferredRevenue	16100000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3113000	USD
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16138000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	10436000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	17107000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43680000	USD
CY2018	us-gaap	Depreciation Depreciation	6100000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.53
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.07
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.80
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5075000	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5100000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9921000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	66269000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25657000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36783000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	484000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	210000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2823000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5753000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	727000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1289000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3553000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5127000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	43680000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66196000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	73000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2017	us-gaap	Depreciation Depreciation	3600000	USD
CY2018Q4	us-gaap	Depreciation Depreciation	4200000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3693000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5206000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7136000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36777000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36192000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-46133000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-83214000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-84225000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16640000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5415000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5400000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	22500000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	22516000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	21346000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-30000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3663000	USD
CY2017	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-204000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2145000	USD
CY2016	us-gaap	Interest Expense InterestExpense	3018000	USD
CY2017	us-gaap	Interest Expense InterestExpense	2702000	USD
CY2018	us-gaap	Interest Expense InterestExpense	1251000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1250000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5046000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	2243000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	1339000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1251000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2786000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9292000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22903000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	508000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4657000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	286000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	7287000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	9136000	USD
CY2016	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-467000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1849000	USD
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-12000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	883000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	451000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	610000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15687000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-28293000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17690000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	360000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	371000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	329000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	413000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3819000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	497000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-192000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-69000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	343000	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1224000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1868000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4231000	USD
CY2016	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	304000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	714000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1726000	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	14000	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	26000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	102000	USD
CY2018	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-1307000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1695000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1215000	USD
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	13025000	USD
CY2016	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1374000	USD
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2348000	USD
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	8075000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	351000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4518000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3400000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-46139000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-83221000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-85063000	USD
CY2016	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	USD
CY2017	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	USD
CY2018	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	800000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-46139000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	733000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	2234000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	5266000	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	765000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1800000	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	4600000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	34332000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	62451000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	342938000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	587403000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19627000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46944000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	149040000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	278417000	USD
CY2017Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	73254000	USD
CY2018Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	77563000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	39840000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	281656000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	293161000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26202000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-170416000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-153028000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36710000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-72235000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-72185000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-88995000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-85063000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-43847000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-76612000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-92942000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5557000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5358000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5273000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	4099000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	42178000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	6105000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	15786000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	838000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1956000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1974000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2046000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-76000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-446000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	449000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	800000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-76000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-446000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	449000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	206000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1059000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4702000	USD
CY2016	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	100000	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7222000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	172000	USD
CY2016	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	USD
CY2017	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	5335000	USD
CY2018	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4386000	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2302000	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	341415000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	236835000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	287450000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1766000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6681000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20203000	USD
CY2018	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1100000	USD
CY2018	us-gaap	Preferred Stock Dividends Shares PreferredStockDividendsShares	253361	shares
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0000001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0000001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018	us-gaap	Profit Loss ProfitLoss	-84263000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26732000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47637000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16036000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31003000	USD
CY2017	us-gaap	Revenues Revenues	49842000	USD
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2018Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1541000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5204000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50714000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	316000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195736000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-280799000	USD
CY2016	us-gaap	Revenues Revenues	25249000	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	254006000	USD
CY2016	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	40049000	USD
CY2017	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	319536000	USD
CY2018	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2016	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2017	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2018	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	41000000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	369383000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	75402000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	154625000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	266000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	753000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3111000	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12000	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	45000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	-46139000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	-83221000	USD
CY2018	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-800000	USD
CY2017Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0	USD
CY2018Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	41800000	USD
CY2016	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	-4000	USD
CY2017	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	244000	USD
CY2018	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	443000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10859000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25562000	USD
CY2018	us-gaap	Revenues Revenues	90639000	USD
CY2016	us-gaap	Royalty Expense RoyaltyExpense	684000	USD
CY2017	us-gaap	Royalty Expense RoyaltyExpense	1100000	USD
CY2018	us-gaap	Royalty Expense RoyaltyExpense	1400000	USD
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	26192000	USD
CY2017	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	32497000	USD
CY2018	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	53465000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1971000	USD
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13053000	shares
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	3670000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	6851000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	5141141	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	3658602	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	699462	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1698790	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3556507	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.49
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	543764	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	883899	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4685577	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2088639	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3325000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7595000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	250495000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3592185	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7391052	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7588405	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.77
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.63
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.58
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3066648	shares
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.25
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.09
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.48
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.57
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.17
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.19
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	104560000	USD
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M6D
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	342946	shares
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1007387	shares
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	249531000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	266000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	753000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2905000	USD
CY2016	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	100000	USD
CY2017	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	7222000	USD
CY2018	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	172000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	83442000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	79696000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	308606000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	483152000	USD
CY2018Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.7378
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1691000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1160000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12582000	shares
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	353000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	884000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1712000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1700000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3427000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	828000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1635000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	80000	USD
CY2018Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	48300000	USD
CY2018Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	1200000	USD
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30403000	shares
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Risk</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also invests in investment‑grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after‑tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.</font></div></div>
CY2018	us-gaap	Revenue Recognition Services Licensing Fees RevenueRecognitionServicesLicensingFees	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered and may continue to enter into license agreements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date none of the Company’s license agreements have been considered to be the acquisition of a business. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval, are evaluated for capitalization considering if the asset is related to research and development and/or has alternative future use. These license agreements may also include contingent consideration in the form of future cash milestone or royalty payments. The Company assesses whether such contingent consideration meets the definition of a derivative. To date, the Company has determined that such contingent consideration are not derivatives. The Company continuously reassesses this determination until such time that the contingency is met or expires.</font></div></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, best estimate of selling price used in the accounting for multiple-element revenue arrangements, estimation of potential credit losses on accounts receivable, the valuation of inventory, stock-based compensation, fair value of common stock and warrants prior to the IPO, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-19-003139-index-headers.html	Edgar Link	pending
0001628280-19-003139-index.html	Edgar Link	pending
0001628280-19-003139.txt	Edgar Link	pending
0001628280-19-003139-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gh-12312018x10k.htm	Edgar Link	pending
gh-12312018x10kxexhibit1019.htm	Edgar Link	pending
gh-12312018x10kxexhibit104a.htm	Edgar Link	pending
gh-12312018x10kxexhibit105a.htm	Edgar Link	pending
gh-12312018x10kxexhibit211.htm	Edgar Link	pending
gh-12312018x10kxexhibit231.htm	Edgar Link	pending
gh-1231x2018x10kxexhibit311.htm	Edgar Link	pending
gh-1231x2018x10kxexhibit312.htm	Edgar Link	pending
gh-1231x2018x10kxexhibit321.htm	Edgar Link	pending
gh-1231x2018x10kxexhibit322.htm	Edgar Link	pending
gh-20181231.xml	Edgar Link	completed
gh-20181231.xsd	Edgar Link	pending
gh-20181231_cal.xml	Edgar Link	unprocessable
gh-20181231_def.xml	Edgar Link	unprocessable
gh-20181231_lab.xml	Edgar Link	unprocessable
gh-20181231_pre.xml	Edgar Link	unprocessable
graphic201806282245ja01.jpg	Edgar Link	pending
graphic3.jpg	Edgar Link	pending
marketopportunity.jpg	Edgar Link	pending
prodmatrixandcarecontinuua1.jpg	Edgar Link	pending
R59.htm	Edgar Link	pending
productmatrixcarecontinuum.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
totalreturnchart2018.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GH
Guardant Health, Inc. Stock $gh

2019 Q1 Form 10-K Financial Statement

#000162828019003139 Filed on March 19, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH Guardant Health, Inc. Stock $gh

2019 Q1 Form 10-K Financial Statement

#000162828019003139 Filed on March 19, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH
Guardant Health, Inc. Stock $gh